GMAB News and Press, Genmab A/S From 05/10/23

2023-05-10 13:11:48 ET Genmab A/S press release ( GMAB ): Q1 GAAP EPS of DKK3.43 beats by DKK3.27 . Revenue of DKK2.26B (+21.5% Y/Y). For further details see: Genmab A/S GAAP EPS of DKK3.43 beats by DKK3.27, revenue of DKK2.26B

May 10 , 202 3 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 3 5 % compared to the first quarter of 2022, to DKK 2,85 4 million “In the f...

2023-05-04 04:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund gained 3.75% (Institutional Shares) during the first q...

2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...

2023-04-25 10:00:20 ET Summary Arbitration dismissal: Genmab's recent dismissal of its second arbitration case against Janssen regarding Darzalex Faspro royalties suggests that these royalties will likely cease after 2030. PDUFA date and pipeline focus: The market's attention shou...

2023-04-25 02:01:13 ET Summary To identify the most promising pharmaceutical companies with a market capitalization of more than $1 billion, we use an eight-step selection process, which will be discussed below. The following two articles will feature our list of the top 10 pharma...

2023-04-24 05:37:42 ET Genmab ( GMAB ) said it is filing a review of an award dismissing its claims in the second arbitration linked to a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Th...

Company Announcement C OPENHAGEN , Denmark; April 24 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under i...

2023-04-21 13:34:59 ET Summary Genmab partnership: argenx and Genmab plan to collaborate to advance antibody therapies in immunology and oncology, leveraging proprietary technologies and sharing costs and profits equally. Q1 2023 sales expectations: Minor headwinds expected in efg...

2023-04-21 06:55:13 ET Genmab ( GMAB ) announced an award in the second arbitration arising under a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Genmab said the arbitral tribunal d...